Arbutus Biopharma’s (ABUS) Buy Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS) in a research report released on Friday morning,Benzinga reports. The brokerage currently has a $5.00 target price on the biopharmaceutical company’s stock. Chardan Capital also issued estimates for Arbutus Biopharma’s FY2025 earnings at ($0.30) EPS.

Several other research analysts have also weighed in on the stock. StockNews.com lowered shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, March 13th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $5.50.

Arbutus Biopharma Stock Performance

Shares of ABUS stock opened at $3.50 on Friday. Arbutus Biopharma has a 52 week low of $2.30 and a 52 week high of $4.73. The stock has a market capitalization of $663.22 million, a PE ratio of -8.14 and a beta of 1.93. The stock’s fifty day moving average is $3.34 and its 200-day moving average is $3.55.

Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings data on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $1.57 million during the quarter, compared to analysts’ expectations of $2.20 million. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. As a group, analysts forecast that Arbutus Biopharma will post -0.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arbutus Biopharma

A number of hedge funds have recently added to or reduced their stakes in ABUS. E Fund Management Co. Ltd. bought a new stake in shares of Arbutus Biopharma during the 4th quarter worth approximately $34,000. Xponance Inc. bought a new stake in Arbutus Biopharma during the fourth quarter worth $34,000. Raymond James Financial Inc. bought a new stake in Arbutus Biopharma during the fourth quarter worth $34,000. Cibc World Markets Corp acquired a new stake in shares of Arbutus Biopharma in the 4th quarter valued at $45,000. Finally, Hsbc Holdings PLC bought a new position in shares of Arbutus Biopharma in the 4th quarter valued at $55,000. Institutional investors own 43.79% of the company’s stock.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.